GB201121513D0 - Thrombin-binding antibody molecules and uses thereof - Google Patents

Thrombin-binding antibody molecules and uses thereof

Info

Publication number
GB201121513D0
GB201121513D0 GBGB1121513.4A GB201121513A GB201121513D0 GB 201121513 D0 GB201121513 D0 GB 201121513D0 GB 201121513 A GB201121513 A GB 201121513A GB 201121513 D0 GB201121513 D0 GB 201121513D0
Authority
GB
United Kingdom
Prior art keywords
thrombin
antibody molecules
binding antibody
binding
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1121513.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB1121513.4A priority Critical patent/GB201121513D0/en
Publication of GB201121513D0 publication Critical patent/GB201121513D0/en
Priority to KR1020147019168A priority patent/KR102114506B1/ko
Priority to PT128066412T priority patent/PT2791177T/pt
Priority to AU2012351858A priority patent/AU2012351858B2/en
Priority to US14/363,514 priority patent/US9518129B2/en
Priority to CN201711384542.3A priority patent/CN107936119B/zh
Priority to RS20171073A priority patent/RS56510B1/sr
Priority to ES12806641.2T priority patent/ES2642718T3/es
Priority to SG11201402560WA priority patent/SG11201402560WA/en
Priority to NZ625386A priority patent/NZ625386B2/en
Priority to EP17177235.3A priority patent/EP3275903A1/en
Priority to RU2017144629A priority patent/RU2017144629A/ru
Priority to HUE12806641A priority patent/HUE034793T2/en
Priority to PCT/GB2012/053140 priority patent/WO2013088164A1/en
Priority to UAA201406892A priority patent/UA116531C2/uk
Priority to HK15103146.0A priority patent/HK1202564B/en
Priority to PE2014000953A priority patent/PE20141706A1/es
Priority to LTEP12806641.2T priority patent/LT2791177T/lt
Priority to SM20170580T priority patent/SMT201700580T1/it
Priority to EP12806641.2A priority patent/EP2791177B1/en
Priority to MX2014007170A priority patent/MX353281B/es
Priority to MEP-2017-243A priority patent/ME02901B/me
Priority to CA2856656A priority patent/CA2856656C/en
Priority to RU2014124985A priority patent/RU2642276C2/ru
Priority to HRP20171775TT priority patent/HRP20171775T1/hr
Priority to MYPI2014001764A priority patent/MY170980A/en
Priority to PE2018002007A priority patent/PE20190171A1/es
Priority to CN201280061294.8A priority patent/CN104053673B/zh
Priority to MX2018000197A priority patent/MX376876B/es
Priority to JP2014546649A priority patent/JP6216954B2/ja
Priority to NO12806641A priority patent/NO2791177T3/no
Priority to BR112014014605A priority patent/BR112014014605A2/pt
Priority to PL12806641T priority patent/PL2791177T3/pl
Priority to DK12806641.2T priority patent/DK2791177T3/en
Priority to SI201231145T priority patent/SI2791177T1/en
Priority to IL232797A priority patent/IL232797B/en
Priority to ZA2014/03836A priority patent/ZA201403836B/en
Priority to PH12014501169A priority patent/PH12014501169B1/en
Priority to US14/309,403 priority patent/US9518128B2/en
Priority to CO14150372A priority patent/CO7101192A2/es
Priority to US15/206,896 priority patent/US9605082B2/en
Priority to US15/348,250 priority patent/US9988463B2/en
Priority to US15/434,639 priority patent/US9988461B2/en
Priority to JP2017165700A priority patent/JP6705785B2/ja
Priority to CY20171101189T priority patent/CY1119599T1/el
Priority to AU2017268655A priority patent/AU2017268655B2/en
Priority to HK18105913.3A priority patent/HK1246326A1/en
Priority to US15/976,595 priority patent/US10370454B2/en
Priority to US15/976,512 priority patent/US10287363B2/en
Priority to US16/363,396 priority patent/US20190276558A1/en
Priority to US16/452,990 priority patent/US11155637B2/en
Priority to US17/344,577 priority patent/US20210371543A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1121513.4A 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof Ceased GB201121513D0 (en)

Priority Applications (52)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
KR1020147019168A KR102114506B1 (ko) 2011-12-14 2012-12-14 트롬빈-결합 항체 분자 및 이의 용도
PT128066412T PT2791177T (pt) 2011-12-14 2012-12-14 Moléculas de anticorpo de ligação a trombina e suas utilizações
AU2012351858A AU2012351858B2 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
US14/363,514 US9518129B2 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
CN201711384542.3A CN107936119B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途
RS20171073A RS56510B1 (sr) 2011-12-14 2012-12-14 Molekuli antitela koji vezuju trombin i njihove upotrebe
ES12806641.2T ES2642718T3 (es) 2011-12-14 2012-12-14 Moléculas de anticuerpos que se unen a la trombina y usos de las mismas
SG11201402560WA SG11201402560WA (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
NZ625386A NZ625386B2 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
EP17177235.3A EP3275903A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
RU2017144629A RU2017144629A (ru) 2011-12-14 2012-12-14 Тромбин-связывающие молекулы антител и их применение
HUE12806641A HUE034793T2 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
UAA201406892A UA116531C2 (uk) 2011-12-14 2012-12-14 Виділена молекула антитіла, яка специфічно зв'язується з ділянкою екзосайта 1 тромбіну, та її застосування
HK15103146.0A HK1202564B (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
PE2014000953A PE20141706A1 (es) 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo
LTEP12806641.2T LT2791177T (lt) 2011-12-14 2012-12-14 Trombiną surišančios antikūnų molekulės ir jų panaudojimas
SM20170580T SMT201700580T1 (it) 2011-12-14 2012-12-14 Molecole di anticorpo di legame della trombina e usi delle stesse
EP12806641.2A EP2791177B1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
MX2014007170A MX353281B (es) 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos.
MEP-2017-243A ME02901B (me) 2011-12-14 2012-12-14 Molekuli antitela koji se vezuju za trombin i njihove upotrebe
CA2856656A CA2856656C (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
RU2014124985A RU2642276C2 (ru) 2011-12-14 2012-12-14 Тромбин-связывающие молекулы антител и их применение
HRP20171775TT HRP20171775T1 (hr) 2011-12-14 2012-12-14 Molekule protutijela koje vežu trombin i njihova uporaba
MYPI2014001764A MY170980A (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof
PE2018002007A PE20190171A1 (es) 2011-12-14 2012-12-14 Anticuerpos de union a trombina y usos del mismo
CN201280061294.8A CN104053673B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途
MX2018000197A MX376876B (es) 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos.
JP2014546649A JP6216954B2 (ja) 2011-12-14 2012-12-14 トロンビン結合性抗体分子及びその使用
NO12806641A NO2791177T3 (https=) 2011-12-14 2012-12-14
BR112014014605A BR112014014605A2 (pt) 2011-12-14 2012-12-14 moléculas de anticorpo de ligação de trombina e usos das mesmas
PL12806641T PL2791177T3 (pl) 2011-12-14 2012-12-14 Cząsteczki przeciwciała wiążące trombinę i ich zastosowania
DK12806641.2T DK2791177T3 (en) 2011-12-14 2012-12-14 THROMBIN-BINDING ANTIBODY MOLECULES AND APPLICATIONS THEREOF
SI201231145T SI2791177T1 (en) 2011-12-14 2012-12-14 Molecules that bind thrombin antibodies and their use
IL232797A IL232797B (en) 2011-12-14 2014-05-26 Thrombin-binding antibody molecules and uses thereof
ZA2014/03836A ZA201403836B (en) 2011-12-14 2014-05-26 Thrombin-binding antibody molecules and uses thereof
PH12014501169A PH12014501169B1 (en) 2011-12-14 2014-05-26 Thrombin-binding antibody molecules and uses thereof
US14/309,403 US9518128B2 (en) 2011-12-14 2014-06-19 Thrombin-binding antibody molecules
CO14150372A CO7101192A2 (es) 2011-12-14 2014-07-11 Anticuerpos de unión a trombina y usos del mismo
US15/206,896 US9605082B2 (en) 2011-12-14 2016-07-11 Thrombin-binding antibody molecules and uses thereof
US15/348,250 US9988463B2 (en) 2011-12-14 2016-11-10 Thrombin-binding antibody molecules and uses thereof
US15/434,639 US9988461B2 (en) 2011-12-14 2017-02-16 Thrombin-binding antibody molecules and uses thereof
JP2017165700A JP6705785B2 (ja) 2011-12-14 2017-08-30 トロンビン結合性抗体分子及びその使用
CY20171101189T CY1119599T1 (el) 2011-12-14 2017-11-14 Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων
AU2017268655A AU2017268655B2 (en) 2011-12-14 2017-12-01 Thrombin-binding antibody molecules and uses thereof
HK18105913.3A HK1246326A1 (en) 2011-12-14 2018-05-08 Thrombin-binding antibody molecules and uses thereof
US15/976,595 US10370454B2 (en) 2011-12-14 2018-05-10 Thrombin-binding antibody molecules and uses thereof
US15/976,512 US10287363B2 (en) 2011-12-14 2018-05-10 Thrombin-binding antibody molecules and uses thereof
US16/363,396 US20190276558A1 (en) 2011-12-14 2019-03-25 Thrombin-Binding Antibody Molecules And Uses Thereof
US16/452,990 US11155637B2 (en) 2011-12-14 2019-06-26 Thrombin-binding antibody molecules and uses thereof
US17/344,577 US20210371543A1 (en) 2011-12-14 2021-06-10 Thrombin-Binding Antibody Molecules And Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
GB201121513D0 true GB201121513D0 (en) 2012-01-25

Family

ID=45560465

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1121513.4A Ceased GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof

Country Status (34)

Country Link
US (5) US9518129B2 (https=)
EP (2) EP2791177B1 (https=)
JP (2) JP6216954B2 (https=)
KR (1) KR102114506B1 (https=)
CN (2) CN107936119B (https=)
AU (2) AU2012351858B2 (https=)
BR (1) BR112014014605A2 (https=)
CA (1) CA2856656C (https=)
CO (1) CO7101192A2 (https=)
CY (1) CY1119599T1 (https=)
DK (1) DK2791177T3 (https=)
ES (1) ES2642718T3 (https=)
GB (1) GB201121513D0 (https=)
HK (1) HK1246326A1 (https=)
HR (1) HRP20171775T1 (https=)
HU (1) HUE034793T2 (https=)
IL (1) IL232797B (https=)
LT (1) LT2791177T (https=)
ME (1) ME02901B (https=)
MX (2) MX376876B (https=)
MY (1) MY170980A (https=)
NO (1) NO2791177T3 (https=)
PE (2) PE20190171A1 (https=)
PH (1) PH12014501169B1 (https=)
PL (1) PL2791177T3 (https=)
PT (1) PT2791177T (https=)
RS (1) RS56510B1 (https=)
RU (2) RU2642276C2 (https=)
SG (1) SG11201402560WA (https=)
SI (1) SI2791177T1 (https=)
SM (1) SMT201700580T1 (https=)
UA (1) UA116531C2 (https=)
WO (1) WO2013088164A1 (https=)
ZA (1) ZA201403836B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
EP3412688A4 (en) * 2016-02-05 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
AU1378495A (en) * 1993-12-27 1995-07-17 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO2001000667A2 (en) 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
AU2001286900A1 (en) 2000-08-31 2002-03-13 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
BRPI0614961A2 (pt) 2005-08-26 2016-09-13 Archemix Corp aptâmero, método, e, composição
EP2001504A2 (en) 2006-03-15 2008-12-17 Emory University Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US20110275701A1 (en) * 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
ES3005912T3 (en) 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
US9518128B2 (en) * 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof

Also Published As

Publication number Publication date
KR20140105556A (ko) 2014-09-01
RU2017144629A (ru) 2019-02-18
MX2014007170A (es) 2015-04-17
PE20141706A1 (es) 2014-11-13
ZA201403836B (en) 2015-12-23
SMT201700580T1 (it) 2018-01-11
CO7101192A2 (es) 2014-10-31
UA116531C2 (uk) 2018-04-10
NZ625386A (en) 2017-03-31
JP2015501830A (ja) 2015-01-19
SI2791177T1 (en) 2018-03-30
CN104053673A (zh) 2014-09-17
DK2791177T3 (en) 2017-12-18
HUE034793T2 (en) 2018-02-28
EP2791177A1 (en) 2014-10-22
IL232797A0 (en) 2014-07-31
US20190276558A1 (en) 2019-09-12
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
EP3275903A1 (en) 2018-01-31
US20180334511A1 (en) 2018-11-22
ES2642718T3 (es) 2017-11-17
HRP20171775T1 (hr) 2017-12-29
CA2856656C (en) 2021-01-19
WO2013088164A1 (en) 2013-06-20
BR112014014605A2 (pt) 2017-06-13
PL2791177T3 (pl) 2018-03-30
SG11201402560WA (en) 2014-06-27
AU2012351858A1 (en) 2014-06-12
KR102114506B1 (ko) 2020-05-22
MX376876B (es) 2025-03-07
HK1246326A1 (en) 2018-09-07
AU2017268655B2 (en) 2019-05-09
RU2017144629A3 (https=) 2021-04-05
HK1202564A1 (en) 2015-10-02
MY170980A (en) 2019-09-23
JP6216954B2 (ja) 2017-10-25
US20140370008A1 (en) 2014-12-18
PH12014501169A1 (en) 2014-09-08
CA2856656A1 (en) 2013-06-20
US10287363B2 (en) 2019-05-14
LT2791177T (lt) 2017-11-27
US20170066842A1 (en) 2017-03-09
US20210371543A1 (en) 2021-12-02
RU2642276C2 (ru) 2018-01-24
CN104053673B (zh) 2018-01-12
RS56510B1 (sr) 2018-02-28
PH12014501169B1 (en) 2014-09-08
US9988463B2 (en) 2018-06-05
PE20190171A1 (es) 2019-02-01
AU2017268655A1 (en) 2017-12-21
US9518129B2 (en) 2016-12-13
NO2791177T3 (https=) 2018-02-03
CY1119599T1 (el) 2018-04-04
IL232797B (en) 2018-07-31
PT2791177T (pt) 2017-11-29
JP6705785B2 (ja) 2020-06-03
ME02901B (me) 2018-04-20
EP2791177B1 (en) 2017-09-06
AU2012351858B2 (en) 2017-10-05
RU2014124985A (ru) 2016-02-10
JP2018039798A (ja) 2018-03-15
MX353281B (es) 2018-01-08

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL272831B (en) Meditops and Meditop binding antibodies and their use
ZA202000056B (en) Engineered microbe-targeting molecules and uses thereof
IL259436A (en) Antibodies against 3angptl and their uses
DK2729170T3 (en) Antibody variants and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201401843B (en) Antibodies against tl1a and uses thereof
IL231846A0 (en) Antibodies against c-met and their uses
ZA201403836B (en) Thrombin-binding antibody molecules and uses thereof
PL2809681T3 (pl) Przeciwciała anty-asic1 i ich zastosowania
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
GB201015790D0 (en) Thrombin-binding antibody molecules and uses thereof
GB201117182D0 (en) Anti-notch antibody molecules and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)